

RESEARCH

Open Access



Residual risk of cardiovascular complications in statin-using patients with type 2 diabetes: the Taiwan Diabetes Registry Study

Chin-Sung Kuo^{1,2}, Nai-Rong Kuo^{1,2}, Yun-Kai Yeh^{1,2}, Yau-Jiunn Lee³, Lee-Ming Chuang⁴, Hua-Fen Chen⁵, Ching-Chu Chen⁶, Chun-Chuan Lee^{7,12}, Chih-Cheng Hsu⁸, Hung-Yuan Li⁹, Horng-Yih Ou^{10,11*†} and Chii-Min Hwu^{1,2*†}

Abstract

Background The residual risks of atherosclerotic cardiovascular disease in statin-treated patients with diabetes remain unclear. This study was conducted to identify factors associated with these residual risks in patients with no prior vascular event.

Methods Data on 683 statin-using patients with type 2 diabetes mellitus (T2DM) from the Taiwan Diabetes Registry were used in this study. Patients aged < 25 or > 65 years at the time of diabetes diagnosis and those with diabetes durations \geq 20 years were excluded. The United Kingdom Prospective Diabetes Study risk engine (version 2.01; <https://www.dtu.ox.ac.uk/riskengine/>) was used to calculate 10-year residual nonfatal and fatal coronary heart disease (CHD) and stroke risks. Associations of these risks with physical and biochemical variables, including medication use and comorbidity, were examined.

Results The 10-year risks of nonfatal CHD in oral anti-diabetic drug (OAD), insulin and OAD plus insulin groups were 11.8%, 16.0%, and 16.8%, respectively. The 10-year risks of nonfatal stroke in OAD, insulin and OAD plus insulin groups were 3.0%, 3.4%, and 4.3%, respectively. In the multivariate model, chronic kidney disease (CKD), neuropathy, insulin use, calcium-channel blocker (CCB) use, higher body mass indices (BMI), low-density lipoprotein (LDL), fasting glucose, log-triglyceride (TG), and log-alanine transaminase (ALT) levels were associated with an increased CHD risk. The residual risk of stroke was associated with CKD, neuropathy, CCB use, and lower LDL cholesterol levels, higher BMI and diastolic blood pressure.

Conclusion This study indicated that insulin was probably a residual risk factor of CHD but not stroke, and that there was a possible presence of obesity paradox in patients with T2DM on statin therapy. In addition to lowering TG and normalizing fasting glucose levels, lower LDL cholesterol level is better for reduction of risk of CHD on statin therapy. On the other hand, lower LDL cholesterol level could potentially be related to higher risk of stroke among populations

[†]Chii-Min Hwu and Horng-Yih Ou have contributed equally to this work and share corresponding authorship.

*Correspondence:
Horng-Yih Ou
wahoryi@mail.ncku.edu.tw
Chii-Min Hwu
chhwu@vghtpe.gov.tw

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

receiving statin therapy. These findings suggest potential therapeutic targets for residual cardiovascular risk reduction in patients with T2DM on statin therapy.

Keywords Diabetes, Residual risk, Statin

Background

The increasing prevalence of type 2 diabetes mellitus (T2DM) is a significant global healthcare concern [1]. According to the United Kingdom Prospective Diabetes Study (UKPDS), nearly half of the deaths that occur within a decade of being diagnosed with diabetes mellitus (DM) are attributable to cardiovascular disease (CVD) [2]. Overall mortality due to vascular complications of DM increased by more than 30% between 2000 and 2016 [3].

Statins play a large role in the reduction of the low-density lipoprotein (LDL) cholesterol level, a main objective in the management of increased CVD risk [4]. A meta-analysis revealed that the occurrence of major vascular events among diabetic patients taking statins declined significantly (by 21%) with every 1 mmol/L decrease in the LDL cholesterol level, but that about 14% of these patients experienced cardiovascular events during a 5-year period [5]. According to the Multi-Ethnic Study of Atherosclerosis [6], this residual atherosclerotic cardiovascular disease (ASCVD) risk in adults under statin treatment without prior ASCVD was associated with older age, male sex, previous or current smoking, higher systolic blood pressure (SBP), antihypertensive medication use, DM, and lower high-density lipoprotein (HDL) cholesterol levels. However, the residual risk has not been investigated thoroughly in patients with T2DM and no prior ASCVD. Furthermore, there is still a controversy over the cardiovascular outcomes of insulin therapy [7–10]. Thus, this study was conducted to identify the effects of insulin use on the residual ASCVD risk and potential associated parameters in patients with T2DM and no prior ASCVD on statin therapy.

Methods

Data sources and subjects

This cross-sectional study was performed with data from the prospective Taiwan Diabetes Registry Study (TDRS) of the Diabetes Association of the Republic of China (Taiwan) [11]. Data from patients with recently diagnosed (<6 months) T2DM, obtained by interviews with certified diabetes educators at the time of TDRS enrollment. Ninety-five primary care clinics and hospitals participated in the TDRS, and enrollment began in October 2015. The study was approved by the institutional review board of Taipei Veterans General Hospital (2015-08-003AC) and Taiwan's Joint Institutional Review Board (14-S-012) and conducted in accordance with the

Declaration of Helsinki. Participants in all studies provided written informed consent.

Study variables

Data for statistical analysis were extracted on patients' age, sex, smoking status, DM duration, history of hepatitis B or C infection, body mass index (BMI), waist circumference, SBP and diastolic blood pressure (DBP), heart rate (HR), complications of DM [cerebrovascular events, coronary and peripheral artery disease, retinopathy, neuropathy, and chronic kidney disease (CKD)], history of comorbidities, blood and urine laboratory findings, and medication use. Cerebrovascular events encompassed hemorrhagic and ischemic stroke. Peripheral artery diseases were those presenting with intermittent claudication, foot ulceration, impalpable pulsation at the dorsalis pedis or posterior tibial artery, and/or amputation history. Retinopathies (proliferative and nonproliferative) were conditions diagnosed with maculopathy and/or unilateral blindness. Neuropathies were defined by abnormal monofilament or vibration test results. CKD was defined by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² (determined using the Cockcroft-Gault equation) and proteinuria (at least trace results of a urine dipstick test or urine albumin-to-creatinine ratio ≥ 30). Medication use encompassed statins, antihypertensives [e.g., angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEis), calcium channel blockers (CCBs), diuretics, and alpha blockers], insulin, and oral antidiabetic drugs (OADs).

Inclusion and exclusion criteria

Data on patients using statins were included in the analysis. To select a population to which the UKPDS risk engine could be applied, patients with non-T2DM, age < 25 or > 65 years at the time of diabetes diagnosis, and diabetes duration ≥ 20 years were excluded. This study further excluded patients who controlled their diabetes solely with lifestyle modifications and did not use insulin or OADs; those with previous CVD (coronary and peripheral artery disease and stroke); and those with serious life-threatening illnesses such as heart failure, renal failure (hemodialysis, peritoneal dialysis, and kidney transplantation), malignancies (e.g., lung, liver, colorectal, breast, endometrial, cervical, stomach, pancreatic, urinary tract, prostate, thyroid, head and neck, and skin cancers), and arrhythmia. Due to the computation of missing cholesterol data, patients with missing HDL

cholesterol and total or LDL cholesterol values and those with triglyceride (TG) levels >500 mg/dL were excluded.

Group allocation and outcomes

The patients were allocated to OAD, insulin, and OAD plus insulin groups. The 10-year risks of nonfatal and fatal coronary heart disease (CHD) and stroke were calculated using the UKPDS risk engine (version 2.01; <https://www.dtu.ox.ac.uk/riskengine/>) and compared among groups. The ability of the study variables to predict these risks was evaluated.

Statistical analysis

Categorical variables are expressed as numbers and percentages and were analyzed using the chi-squared test. Continuous variables are expressed as means \pm standard deviations and were examined using analysis of variance, followed by Sheffé's multiple comparison post hoc test. In risk calculation using the UKPDS risk engine, 95% confidence intervals were calculated and missing fasting glucose, creatinine, and eGFR data were imputed using multiple imputation by chained equations with the R studio cloud [12]. Missing cholesterol data were computed using the equation total cholesterol = TG/5 + HDL cholesterol + LDL cholesterol. Patients with computed HDL cholesterol values <0 mg/dL and those with risk values exhibiting error due to small HDL cholesterol values were excluded from further analysis.

To evaluate the ability of physical and biochemical variables to predict the 10-year risks of nonfatal and fatal CHD and stroke, univariate linear regression models were constructed first. Serum TG and alanine transaminase (ALT) values were also analyzed as natural logarithms (logTG and logALT). Variables with P values <0.05 in the univariate analysis and those with the smallest P values between TG/logTG, ALT/logALT, and serum creatinine/eGFR were entered into multivariate regression models. The statistical analyses were conducted with SPSS software (version 23.0 for Windows; IBM Corporation, Armonk, NY, USA) and a significance level of $P < 0.05$.

Results

Patient characteristics

Of 1147 diabetic patients using statins identified, data from 683 were included in the final analysis (Fig. 1). The OAD, insulin, and OAD plus insulin groups contained 576, 30, and 77 patients, respectively.

The patients' characteristics are presented in Table 1. Subjects using OAD alone (50.7 ± 9.2 years old) are older in diabetes onset compared to those under therapy of both OAD and insulin (48.0 ± 9.4 years old) ($P = 0.021$). Subjects using OADs and insulin (5.6 ± 7.2 years) had longer DM durations than did those using insulin alone

(2.5 ± 5.3 years) ($P = 0.038$) or OADs alone (2.3 ± 4.8 years) ($P < 0.001$). The glycated hemoglobin (HbA1c) concentration was higher in the insulin alone group (9.6 ± 2.8) ($P = 0.004$) and insulin-OAD combination group (9.1 ± 2.5) ($P = 0.002$) compared to the OADs alone group (8.1 ± 2.2). Subjects using both OADs and insulin (16/77, 20.8%) were more likely to develop CKD than were those using OADs alone (58/576, 10.1%) ($P = 0.011$).

The 10-year risks of nonfatal CHD in OAD, insulin and OAD plus insulin groups were 11.8%, 16.0%, and 16.8%, respectively. The 10-year risks of fatal CHD in OAD, insulin and OAD plus insulin groups were 6.4%, 9.6%, and 10.9%, respectively. The 10-year risks of nonfatal stroke in OAD, insulin and OAD plus insulin groups were 3.0%, 3.4%, and 4.3%, respectively. The 10-year risks of fatal stroke in OAD, insulin and OAD plus insulin groups were 0.3%, 0.4%, and 0.4%, respectively. Patients who used both insulin and OAD (16.8%, 95% CI 12.5~21.1%) had higher 10-year risk of nonfatal ($P = 0.025$) CHD, compared to those under OAD monotherapy (11.8%, 95% CI 10.6~13.0%). Similarly, patients who used both insulin and OAD (10.9%, 95% CI 7.5~14.3%) had higher 10-year risk of fatal ($P = 0.002$) CHD, compared to those under OAD monotherapy (6.4%, 95% CI 5.6~7.1%). On the contrary, there was no significant difference in 10-year risk of nonfatal and fatal CHD between those under insulin alone and OAD alone, or between insulin alone and combination therapy. Patients who used both insulin and OAD (4.3%, 95% CI 3.2~5.5%) had higher 10-year risk of nonfatal stroke ($P = 0.043$), compared to those under OAD monotherapy (3.0%, 95% CI 2.7~3.4%). Nevertheless, there were no significant difference between either two groups in the 10-year risk of fatal stroke. (Fig. 2).

Factors associated with the nonfatal and fatal CHD risks

Table 2 showed clinical and laboratory factors and their standardized coefficients (β) that predict the 10-year risks of nonfatal and fatal CHD and stroke.

In the univariate model, patients having diabetic complications including neuropathy and CKD, those with higher logTG, LDL cholesterol, fasting glucose, and those under medications such as CCB and insulin were associated with significantly greater risks of nonfatal CHD (Table 2). Similarly, greater risks of fatal CHD were associated with neuropathy and CKD; higher logTG, LDL cholesterol, fasting glucose, and the use of CCB and insulin. Lower BMI and lower logALT were associated with a greater nonfatal CHD risk. Similarly, greater risks of fatal CHD were associated with lower BMI and lower logALT (Table 2).

In the multivariate model, lower BMI and lower logALT level; higher logTG, LDL cholesterol, fasting glucose, CCB and insulin use were associated independently with a greater nonfatal CHD risk (Table 2). Similarly, in




Fig. 1 Flowchart of study subject selection process

the multivariate model, greater risk of fatal CHD was independently associated with lower BMI and lower logALT level; higher logTG, LDL cholesterol, fasting glucose, CCB and insulin use (Table 2).

Factors associated with nonfatal and fatal stroke risks

In the univariate model, diabetic patients complicated with CKD and neuropathy, having lower DBP, BMI, LDL cholesterol, and logALT, and using medications including ARB, CCB, diuretics were at an elevated nonfatal 10-year stroke risk (Table 3). Among the above-mentioned factors, lower DBP, BMI, and LDL cholesterol, and the use of CCB remained significant in the multivariate analysis (Table 3).

In the univariate model, an increased residual risk of fatal stroke was associated with diabetic complications including retinopathy, neuropathy, CKD. In addition, patients with lower BMI, LDL cholesterol, and logALT and those using ARB, CCB, and diuretics were associated with higher risks of fatal stroke (Table 3). In the

multivariate regression model, independent risk factors of fatal stroke included lower BMI, logALT, and the use of CCB (Table 3).

Discussion

This study identified factors affecting the residual risks of CHD and stroke in patients with diabetes under statin treatment. In addition to CKD, neuropathy, and insulin and CCB use, higher LDL, fasting glucose, and logTG levels were associated with an increased CHD risk. This study advances knowledge in this area by further showing that higher BMI and logALT values were associated with a reduced risk of CHD in this population. The residual risk of stroke was associated with CKD, neuropathy, CCB use, and low LDL cholesterol levels, lower BMI and lower DBP in this study. The reduction of both residual risks of CHD and stroke with higher BMI suggests that the obesity paradox can be applied to patients with T2DM on statin therapy.

Table 1 Baseline characteristics of the study cohort by different treatments of diabetes

Characteristic	OAD (n=576)	Insulin (n=30)	OAD+Insulin (n=77)	P
Age (years)	53.1±10.4	50.3±10.6	53.6±11.2	0.33
Male, n (%)	340 (59)	14 (47)	44 (57)	0.40
Smoking, n (%)	124 (21.5)	12 (40.0)	15 (19.5)	
Ex-smoking, n (%)	71 (12.3)	2 (6.7)	10 (13.0)	*0.18
Body mass index (kg/m ²)	27.5±5.2	26.8±3.8	27.2±4.2	0.76
Waist (cm)	91.6±11.4	92.6±12.2	91.6±10.5	0.89
Systolic BP (mmHg)	131.1±16.7	131.2±19.3	133.4±14.1	0.53
Diastolic BP (mmHg)	79.5±11.0	80.6±11.7	78.3±11.1	0.56
Diabetes history				
Diabetes onset (years)	50.7±9.2	47.8±9.9	48.0±9.4	0.02
Diabetes duration (years)	2.3±4.8	2.5±5.3	5.6±7.2	<0.01
Diabetes complications				
CKD n (%)	58 (10.1)	6 (20)	16 (20.8)	0.01
Retinopathy, n (%)	49 (8.5)	2 (6.7)	8 (10.4)	0.80
Neuropathy, n (%)	12 (2.1)	0 (0)	3 (3.9)	0.42
Medications, n (%)				
ACEi	14 (2.4)	0 (0)	3 (3.9)	0.50
Diuretic	37 (6.4)	3 (10.0)	6 (7.8)	0.69
CCB	85 (14.8)	5 (16.7)	14 (18.2)	0.72
ARB	121 (21.0)	6 (20.0)	22 (28.6)	0.31
Alpha blocker	5 (0.9)	0 (0)	1 (1.3)	0.81
Laboratory data				
TC (mg/dL)	188.0±51.1	195.3±60.6	187.3±46.6	0.73
HDL (mg/dL)	45.0±15.4	42.1±16.5	44.9±17.8	0.61
LogTG	2.17±0.26	2.21±0.30	2.15±0.26	0.53
LDL (mg/dl)	108.2±38.6	115.3±46.6	108.7±41.7	0.63
LogALT	1.44±0.27	1.43±0.25	1.42±0.26	0.64
Fasting glucose (mg/dL)	152.3±61.7	164.4±92.7	169.1±84.9	0.09
HbA1c (%)	8.1±2.2	9.6±2.8	9.1±2.5	<0.01
Creatinine (mg/dl)	0.86±0.29	0.89±0.38	0.95±0.37	0.05

Multiple imputation by chained equations was applied for missing fasting glucose (n=6), creatinine (n=1), and eGFR (n=1) values

Obesity is known to increase the CVD risk in the general population [13], but to prolong survival in patients with CVD [14]. The obesity paradox has also been reported to apply to patients with T2DM, possibly because genetically susceptible individuals develop T2DM at lower BMIs and have elevated risks of other diseases and complications, and thus poor prognoses [15, 16]. Another explanation is that confounding factors have not been addressed properly in previous research, potentially leading to the underestimation of the effect of the BMI on the mortality risk [17]. The underlying mechanism of obesity paradox in this study needs further research to be clarified.

Interestingly, the role of LDL cholesterol in residual risks of CHD showed different from in that of stroke in this study. There is expansion of evidence in “lower is better” principle of LDL cholesterol management for prevention of CHD [18, 19]. In concordance with the previous findings, lower LDL cholesterol levels were associated with the reduced risk of CHD among populations receiving statin therapy in this study.

Furthermore, previous reports demonstrated that lipid-lowering therapy reduced risks of ischemic stroke but increased risks of hemorrhagic stroke [20]. In this study, lower LDL cholesterol levels associated with higher risk of stroke. One possible explanation might be increased risks of hemorrhagic stroke. The adequate LDL cholesterol target in patients with T2DM on statin therapy would need individual consideration of prevention CHD or stroke.

This study demonstrated that higher LDL cholesterol and lower logALT levels were residual risk factors of CHD. Consistently, in the Treating to New Targets study, higher atorvastatin dosages were associated with lower LDL cholesterol levels, higher ALT levels, and fewer first major cardiovascular events in patients with diabetes [21]. The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial also demonstrated that the statin dose was related positively to the incidence of transaminitis [22]. The possible explanation is that higher ALT levels associated with higher statin dose and lower CHD complications.




Fig. 2 Residual risk of nonfatal, fatal coronary heart disease and stroke in oral antidiabetic drug (OAD) monotherapy group, insulin monotherapy group, and OAD+Insulin dual therapy group

Insulin use was a residual risk factor of CHD but not stroke in this study. The cardiovascular outcomes of insulin therapy remain controversial. Findings from the large Action to Control Cardiovascular Risk in Diabetes [7] and Outcome Reduction with Initial Glargine Intervention [8] randomized controlled trials suggest that insulin has a neutral effect on cardiovascular diseases, whereas some observational studies [9, 10] have revealed that it substantially increases cardiovascular risks. This discrepancy can be explained in part by confounding by factors such as diabetes severity and renal impairment [23]. However, multivariate analyses were adjusted for these factors in this study. Another possible explanation is that insulin users in population of this study were younger at diabetes onset and had higher HbA1c concentrations (independent risk

factors for adverse cardiovascular events [24]) relative to non-users.

In adjusted analyses of this study, higher DBP was associated with better stroke outcomes. This finding suggests that the CVD risk increases with the pulse pressure, consistent with the demonstration in a meta-analysis that CVD-related mortality increases by nearly 20% with a 10-mm Hg increase in the pulse pressure [25]. The increased CVD risk with low DBP has been attributed to decreased perfusion to vital organs and the parallel increase in SBP with age-related arterial stiffening [26].

This study suggested that logTG was a residual risk factor for CHD. This finding is supported by a previous retrospective study showing a strong association between TG levels greater than 150 mg/dL and initial

Table 2 Univariate and multivariate linear regression analyses of clinical variables and indices in predicting nonfatal and fatal coronary heart disease

	Nonfatal CHD						Fatal CHD					
	Univariate			Multivariate (R square = 0.281)			Univariate			Multivariate (R square = 0.238)		
	β	(95% CI)	p value	β	(95% CI)	p value	β	(95% CI)	p value	β	(95% CI)	p value
BMI	-0.003	(-0.002, -0.004)	0.008	-0.003	(-0.002, -0.004)	0.002	-0.0025	(-0.0018, -0.0034)	0.003	-0.002	(-0.001, -0.003)	0.004
Waist	0.0004	(0.0014, -0.0006)	0.413				0.00005	(0.0004, -0.0003)	0.897			
DBP	0.001	(0.0014, 0.0004)	0.071				0.0051	(0.0055, 0.0047)	0.187			
Complications												
CKD	0.095	(0.112, 0.078)	<0.001	0.080	(0.096, 0.064)	<0.001	0.086	(0.099, 0.073)	<0.001	0.073	(0.085, 0.061)	<0.001
Retinopathy	0.001	(0.021, -0.019)	0.957				0.016	(0.031, 0.001)	0.300			
Neuropathy	0.091	(0.130, 0.052)	0.019	0.074	(0.107, 0.041)	0.028	0.07	(0.099, 0.041)	0.017	0.054	(0.080, 0.028)	0.037
Medications												
ACEI	-0.014	(0.023, -0.051)	0.713				-0.002	(0.026, -0.03)	0.931			
Diuretics	0.014	(0.037, -0.009)	0.547				0.021	(0.038, 0.004)	0.222			
CCB	0.035	(0.051, 0.019)	0.029	0.031	(0.045, 0.017)	0.027	0.039	(0.051, 0.027)	0.001	0.035	(0.046, 0.024)	0.001
ARB	0.012	(0.026, -0.002)	0.402				0.02	(0.03, 0.01)	0.061			
Alpha	0.076	(0.137, 0.015)	0.213				0.075	(0.121, 0.029)	0.105			
Insulin	0.055	(0.071, 0.039)	<0.001	0.035	(0.045, 0.017)	0.011	0.051	(0.063, 0.039)	<0.001	0.033	(0.044, 0.022)	0.002
OAD	-0.043	(-0.015, -0.071)	0.122				-0.029	(-0.008, -0.05)	0.162			
Laboratory data												
LogTG	0.189	(0.209, 0.169)	<0.001	0.149	(0.179, 0.139)	<0.001	0.093	(0.109, 0.077)	<0.001	0.064	(0.080, 0.048)	<0.001
LDLc	0.001	(0.0011, 0.0009)	<0.001	0.001	(0.00113, 0.0009)	<0.001	0.00046	(0.00057, 0.00035)	<0.001	0.00311	(0.0032, 0.0030)	<0.001
LogALT	-0.048	(-0.026, -0.070)	0.026	-0.047	(-0.027, -0.065)	0.018	-0.053	(-0.037, -0.069)	0.001	-0.042	(-0.027, -0.057)	0.005
Fasting glucose	0.001	(0.00108, 0.00092)	<0.001	0.001	(0.0011, 0.0009)	<0.001	0.0005	(0.00058, 0.00046)	<0.001	0.0004	(0.0005, 0.0003)	<0.001

Table 3 Univariate and multivariate linear regression analyses of clinical variables and indices in predicting nonfatal and fatal stroke

	Nonfatal stroke						Fatal Stroke					
	Univariate			Multivariate (R square = 0.140)			Univariate			Multivariate (R square = 0.153)		
	β	(95% CI)	p value	β	(95% CI)	p value	β	(95% CI)	p value	β	(95% CI)	p value
BMI	-0.002	(-0.001, -0.003)	0.001	-0.002	(-0.001, -0.003)	0.011	-0.00028	(-0.00012, -0.0004)	0.008	-0.0003	(-0.0001, -0.0004)	0.018
Waist	0.00004	(0.00034, -0.00026)	0.872			0.000021		0.658				
DBP	-0.001	(-0.0007, -0.0013)	0.008	-0.001	(-0.0007, -0.0013)	0.041	0.0000003	(0.00005, -0.00005)	0.995			
Complications												
CKD	0.063	(0.072, 0.054)	<0.001	0.053	(0.062, 0.044)	<0.001	0.012	(0.014, 0.01)	<0.001	0.01	(0.012, 0.008)	<0.001
Retinopathy	0.019	(0.03, 0.008)	0.081			0.005		(0.007, 0.003)	0.019	0.002	(0.0035, -0.001)	0.332
Neuropathy	0.061	(0.082, 0.04)	0.004	0.046	(0.066, 0.026)	0.033	0.011	(0.015, 0.007)	0.002	0.008	(0.011, 0.005)	0.021
Medications												
ACEI	0.024	(0.044, 0.004)	0.229			-0.001		(0.002, -0.004)	0.747			
Diuretics	0.035	(0.047, 0.023)	0.004	0.013	(0.026, -0.0006)	0.340	0.006	(0.008, 0.004)	0.004	0.001	(0.003, -0.001)	0.567
CCB	0.046	(0.054, 0.038)	<0.001	0.033	(0.042, 0.024)	<0.001	0.009	(0.01, 0.008)	<0.001	0.006	(0.008, 0.004)	<0.001
ARB	0.027	(0.034, 0.02)	<0.001	0.005	(0.014, -0.004)	0.085	0.006	(0.007, 0.005)	<0.001	0.002	(0.003, 0.001)	0.288
Alpha	0.057	(0.09, 0.024)	0.085				0.009	(0.015, 0.003)	0.133			
Insulin	0.009	(0.017, 0.001)	0.279			0.00147		(0.00296, -0.00002)	0.344			
OAD	0.00002	(0.015, -0.015)	0.999			-0.00296		(-0.00036, -0.00556)	0.911			
Laboratory data												
LogTG	0.008	(0.020, -0.004)	0.491			0.001		(0.003, -0.001)	0.677			
LDLc	-0.00025	(-0.00017, -0.00033)	0.001	-0.0002	(-0.0001, -0.0003)	0.038	-0.00003	(-0.00002, -0.00004)	0.017	-0.00002	(-0.00001, -0.00003)	0.068
LogALT	-0.041	(-0.029, -0.053)	0.001	-0.022	(-0.009, -0.033)	0.073	-0.008	(-0.006, -0.010)	<0.001	-0.005	(-0.003, -0.007)	0.010
Fasting glucose	0.00064	(0.00069, 0.00059)	0.169			0.000003		(0.000011, -0.000005)	0.715			

BMI, body mass index; DBP, diastolic blood pressure; CKD, chronic kidney disease; ACEi, angiotensin converting enzyme inhibitors; CCB, calcium channel blocker; ARB, angiotensin receptor blocker; OAD, oral antidiabetic drug; TG, triglyceride; LDL, low-density lipoprotein cholesterol; ALT, alanine transaminase

major adverse cardiovascular events among statin-treated diabetic patients with LDL cholesterol levels <100 mg/dL [27]. Hypertriglyceridemia-related subclinical atherosclerosis and vascular inflammation may contribute to atherosclerotic plaque development and subsequent cardiovascular events independently of the LDL cholesterol concentration [27, 28]. These findings suggest that the reduction of the TG level is a potential target for the reduction of the residual risks of CHD events in diabetic patients with LDL concentrations falling within guideline recommendations.

In agreement with previous findings, this study showed that CKD is a risk factor for poor cardiovascular outcomes in patients with diabetes under statin treatment. An analysis of data from the Third National Health and Nutrition Examination Survey showed that CKD was associated independently with an increased cardiovascular mortality risk among patients with diabetes [29]. Statins were found to protect against cardiovascular complications in patients with diabetes and CKD in one study [30], but to have reduced efficacy with deteriorating renal function in a meta-analysis [31]. These findings may be explained by the occurrence of vascular calcification in advanced CKD [32].

Peripheral neuropathy was a residual risk factor for CHD and stroke in this study. In diabetic patients, neuropathy shares risk factors with cardiovascular complications [33]. Peripheral neuropathy independently predicts initial CVD in patients with T2DM [34]. The association of peripheral neuropathy with cardiovascular events likely reflects the involvement of common pathways, including systemic inflammation [35] and lipid dysmetabolism [36], which may be reversed by statin therapy [37]. The cross-sectional and longitudinal Fremantle Diabetes Study showed that statins prevented diabetic neuropathy [38], potentially due to their lipid-lowering, endothelial cell-activating, and anti-inflammatory effects. However, other pathogenetic mechanisms, such as the chronic hyperglycemia-facilitated deposition of advanced glycation end products in nerves [39] and vessels [40], which leads to diabetic neuropathy and cardiovascular events, are not related clearly to statin use.

Current American Diabetes Association guidelines recommend an ACEi or ARB as the first-line medication for diabetes, especially in patients with proteinuria, and the addition of CCB as a second-line medication [41]. The observed association of CCB use with increased CHD and stroke risks [42] could be explained by polypharmacy-related poor cardiovascular drug compliance and the subsequent increased risk of adverse outcomes [43].

Study strengths and limitations

The strengths of this study include that TDRS is a nationwide, multicenter study conducted by well-trained health professionals to assess real-world clinical practices and outcomes for patients with diabetes in Taiwan. The data containing anthropometric measures, laboratory results and medical records allowed detailed investigation of potential effects of insulin use and the residual ASCVD risks thoroughly in patients with T2DM and no prior ASCVD. However, this study has several limitations. Its cross-sectional design prevented the establishment of causal relationships; prospective longitudinal studies are needed to investigate the causal relationships between residual risk factors and cardiovascular outcomes. In addition, the types, dosages, and use durations of statins and anti-diabetic medications were not included in the study data and thus were not examined. Variation in the underlying mechanisms, potency, and side effects of medications in the same class may influence patient adherence, laboratory findings, and the endpoints examined in this study. Furthermore, this study used BMI to infer "obesity paradox". However, BMI is not synonymous with excess adiposity, measured by body fat percentage. Further research may include measurements of body composition and their distribution for elucidation of obesity paradox. Additionally, data from the present study were insufficient to differentiate between ischemic and hemorrhagic strokes in the analysis.

Conclusions

Based on the findings of this study, insulin may possibly increase risk of CHD but not stroke in statin-treated patients with T2DM. To use of higher statin doses would be suggested to lower LDL cholesterol levels, even with ALT elevation, to further reduce CHD risks in patients with T2DM. On the other hand, lower LDL cholesterol level and lower DBP related to higher risk of stroke among populations receiving statin therapy. Therefore, in patients with T2DM on statin therapy, a higher LDL cholesterol target may possibly be acceptable in those with lower DBP. Under statin therapy and with the control of other known risk factors, residual cardiovascular risks may be lower in obese than in non-obese subjects with T2DM. CKD, neuropathy, and higher TG levels were also residual risk factors in this study, as was the use of CCBs, possibly representing poly-antihypertensive agent use. This study suggests conservative initiation of insulin, cautious use of CCBs and potential therapeutic targets for residual ASCVD risk reduction in patients with T2DM on statin therapy.

Abbreviations

ACEis	Angiotensin-converting enzyme inhibitors
ALT	Alanine transaminase
ARBs	Angiotensin receptor blockers
ASCVD	Atherosclerotic cardiovascular disease
BMI	Body mass index
CCB	Calcium-channel blocker
CHD	Coronary heart disease
CKD	Chronic kidney disease
CVD	Cardiovascular disease
DBP	Diastolic blood pressure
DM	Diabetes mellitus
eGFR	Estimated glomerular filtration rate
HbA1c	Glycated hemoglobin
HDL	High-density lipoprotein
HR	Heart rate
LDL	Low-density lipoprotein
OAD	Oral anti-diabetic drug
SBP	Systolic blood pressure
T2DM	Type 2 diabetes mellitus
TDRS	Taiwan Diabetes Registry Study
TG	Triglyceride
UKPDS	United Kingdom Prospective Diabetes Study

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12944-023-02001-z>.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

The authors appreciate the contributions of all members of TDRS committee in the Diabetes Association of the Republic of China (Taiwan).

Author contributions

C.M.H. and H.Y.O. developed the study design and proposed research plan. C.S.K., L.M.C., H.F.C., C.C.C., C.C.L., H.Y.L., H.Y.O. and C.M.H. collected and contributed the patient data. N.R.K., Y.K.Y. and C.C.H. analyzed and interpreted the patient data. C.S.K. and N.R.K. were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Science and Technology Council, Taiwan (MOST 110-2314-B-075-027-MY3) and the Taipei Veterans General Hospital (V110C-165, V110C-175, V111C-188, V111C-190, V112C-164).

Data availability

The data that support the findings of this study are available from Taiwan Diabetes Registry but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Taiwan Diabetes Registry.

Declarations

Ethics approval and consent to participate

The study (project approved number: TDR20-16) was approved by the institutional review board of Taipei Veterans General Hospital (2015-08-003AC) and Taiwan's Joint Institutional Review Board (14-S-012) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

Consent for publication

Participants signed informed consent for the publication of their data.

Competing interests

The authors declare no competing interests.

Author details

¹Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, 112, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan

²School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

³Department of Internal Medicine, Lee's Endocrinology Clinic, Pingtung, Taiwan

⁴Division of Endocrinology & Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC

⁵Section of Endocrinology and Metabolism, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan

⁶Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan

⁷Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan

⁸Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli, Taiwan

⁹Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

¹⁰Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

¹¹College of Medicine, National Cheng Kung University, Tainan, Taiwan

¹²Department of Medicine, MacKay Medical College, New Taipei City, Taiwan

Received: 5 November 2023 / Accepted: 31 December 2023

Published online: 23 January 2024

References

1. Khan MAB, et al. Epidemiology of type 2 diabetes - global burden of Disease and Forecasted trends. *J Epidemiol Glob Health*. 2020;10(1):107–11.
2. *Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)*. UK prospective diabetes study (UKPDS) Group. *Lancet*. 1998. 352(9131): p. 854–65.
3. Ling W, et al. Global trend of diabetes mortality attributed to vascular complications, 2000–2016. *Cardiovasc Diabetol*. 2020;19(1):182.
4. Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. *J Am Coll Cardiol*. 2014;63(25 Pt B):2889–934.
5. Trialists CT. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008;371(9607):117–25.
6. Wong ND, et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis. *J Clin Lipidol*. 2017;11(5):1223–33.
7. Action to Control Cardiovascular Risk in Diabetes Study. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358(24):2545–59.
8. Investigators OT, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367(4):319–28.
9. Roumie CL, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. *JAMA*. 2014;311(22):2288–96.
10. Currie CJ, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. *J Clin Endocrinol Metab*. 2013;98(2):668–77.
11. Wang JS, et al. Distinct associations of self-monitoring of blood glucose with glycemic control and hypoglycemia between groups of recently diagnosed and long-term follow-up type 2 diabetes: the Taiwan Diabetes Registry. *Int J Clin Pract*. 2021;75(9):e14410.
12. Team R. *RStudio: Integrated Development Environment for R [Internet]*. Boston, MA 2015.
13. Adams KF, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. *N Engl J Med*. 2006;355(8):763–78.
14. Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. *Curr Hypertens Rep*. 2010;12(2):120–6.
15. Costanzo P, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. *Ann Intern Med*. 2015;162(9):610–8.

16. Carnethon MR, et al. Association of weight status with mortality in adults with incident diabetes. *JAMA*. 2012;308(6):581–90.
17. Tobias DK, et al. Body-mass index and mortality among adults with incident type 2 diabetes. *N Engl J Med*. 2014;370(3):233–44.
18. Mach F, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111–88.
19. Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*, 2019. 73(24):3168–3209.
20. Hackam DG, Hegele RA. Cholesterol lowering and Prevention of Stroke. *Stroke*. 2019;50(2):537–41.
21. LaRosa JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005;352(14):1425–35.
22. Cannon CP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*. 2004;350(15):1495–504.
23. Gamble JM, et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. *Lancet Diabetes Endocrinol*. 2017;5(1):43–52.
24. Huo L, et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011. *Diabetologia*. 2018;61(5):1055–63.
25. Blacher J, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. *Arch Intern Med*. 2000;160(8):1085–9.
26. Kannel WB, et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. *Am J Cardiol*. 2004;94(3):380–4.
27. Ambrosy AP, et al. Triglyceride levels and residual risk of atherosclerotic Cardiovascular Disease events and death in adults receiving statin therapy for primary or secondary Prevention: insights from the KP REACH study. *J Am Heart Assoc*. 2021;10(20):e020377.
28. Raposeiras-Roubin S, et al. Triglycerides and residual atherosclerotic risk. *J Am Coll Cardiol*. 2021;77(24):3031–41.
29. Afkarian M, et al. Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol*. 2013;24(2):302–8.
30. Baigent C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011;377(9784):2181–92.
31. Hou W, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. *Eur Heart J*. 2013;34(24):1807–17.
32. Jankowski J, et al. Cardiovascular Disease in chronic kidney disease: pathophysiological insights and therapeutic options. *Circulation*. 2021;143(11):1157–72.
33. Tesfaye S, et al. Vascular risk factors and diabetic neuropathy. *N Engl J Med*. 2005;352(4):341–50.
34. Brownrigg JR, et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. *Heart*. 2014;100(23):1837–43.
35. Kellogg AP, et al. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. *Diabetes*. 2007;56(12):2997–3005.
36. Rumora AE, et al. Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. *Ann Clin Transl Neurol*. 2021;8(6):1292–307.
37. Mohler ER 3, et al. The Effect of Testosterone on Cardiovascular biomarkers in the testosterone trials. *J Clin Endocrinol Metab*. 2018;103(2):681–8.
38. Davis TM, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia*. 2008;51(4):562–6.
39. Sugimoto K, et al. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. *Diabetologia*. 1997;40(12):1380–7.
40. Hedrick CC, et al. Glycation impairs high-density lipoprotein function. *Diabetologia*. 2000;43(3):312–20.
41. Passarella P, et al. Hypertension management in diabetes: 2018 update. *Diabetes Spectr*. 2018;31(3):218–24.
42. Kulkarni SP, et al. Long-term adherence with cardiovascular drug regimens. *Am Heart J*. 2006;151(1):185–91.
43. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.